Aspirin resistance in patients with impaired renal functions

Kardiologia Polska

Volumn 72, Issue 4, 2014, Pages 331-338

  Aksu, Hale Unal ^a   Oner, Ender ^a   Erturk, Mehmet ^a   Aksu, Huseyin ^a   Isiksacan, Nilgun ^a   Ozalp, Begum ^a   Akture, Gulsah ^a   Akbay, Ertan ^a   Ozer, Leyla ^b   Erol, Mustafa Kemal ^a  

^a MEHMET AKIF ERSOY THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Aspirin resistance; Chronic kidney disease; Coronary artery disease

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE VOLUME; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG RESISTANCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

ADULT; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84940280306     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.a2013.0286     Document Type: Article

References (28)

1. Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanism of action. Stroke, 1990; 21: 12-23.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature, 1971; 231: 232-235.
3. Antithrombotic Trialists, Collaboration collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324: 71-86.
4. Sane DC, McKee SA, Malinin AI, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol, 2002; 90: 893-895.
5. Hurlen M, Seljeflot I, Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J, 1998; 32: 233-237.
6. Gum PA, Kottke-Marchant K, Poggio ED et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol, 2001; 88: 230-235.
7. Gum PA, Kottke-Marchant K, Welsh PA et al. A prospective, blinder determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol, 2003; 41: 961-965.
8. Grotemeyer KH. Effects of acetyl salicyclic acid in stroke patients; evidence of non-responders in a subpopulation of treated patients. Thromb Res, 1991; 63: 587-593.
9. Mueller MR, Salat A, Stangl P et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemostasis, 1997; 78: 1003-1007.
10. Catteneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Aterioscler Throm Vasc Biol, 2004; 24: 1980-1987.
11. Krasopoulos G, Brister SJ, Beattie WS et al. Aspirin " resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ, 2008; 336: 195-198.
12. Szczeklik A, Musiat J, Undas A, Sanak M. Aspirin resistance. J Thromb Haemost, 2005; 3: 1655-1662.
13. Grinstein J, Cannon CP. Aspirin resistance: current status and role of tailored therapy. Clin Cardiol, 2012; 35: 673-681.
14. Baigent C, Landray M, Leaper C et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis, 2005; 45: 473-484.
15. Geara AS, Azzi N, Bassil C, El-Sayegh S. Aspirin resistance in hemodialysis patients. Int Urol Nephrol, 2012; 44: 323-325.
16. Tanrikulu AM, Ozben B, Koc M et al. Aspirin resistance in patients with chronic renal failure. J Nephrol, 2011; 24: 636-646.
17. Kilickesmez KO, Kocas C, Abaci O et al. Follow-up of aspirin-resistant patients with end-stage kidney disease. Int Urol Nephrol, 2013; 45: 1097-1102.
18. Levey AS, Greene T, Schluchter MD et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol, 1993; 4: 1159-1171.
19. von Pape KW, Dzijan-Horn M, Bohner J et al. Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays: PFA-100 and Multiple. Hamostaseologie, 2007; 27: 155-160.
20. Gum PA, Kottke-Marchant K, Welsh PA et al. A prospective, blinder determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol, 2003; 41: 961-965.
21. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 39: S1-S266.
22. Blann AD, Kuzniatsova N, Velu S, Lip GYH. Renal function and aspirin resistance in patients with coronary artery disease. Thromb Res, 2012; 130: e103-e106.
23. Würtz M, Wulff LN, Grove EL et al. Influence of renal function and platelet turnover on the antiplatelet effect of aspirin. Thromb Res, 2012; 129: 434-440.
24. Oberg BP, McMenamin E, Lucas FL et al. Increased prevalence of oxidant stres and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int, 2004; 65: 1009-1016.
25. Bloom A, Greaves M, Preston FE, Brown CB. Evidence against a platelet cyclooxygenase defect in uraemic subjects on chronic haemodialysis. Br J Haematol, 1986; 62: 143-149.
26. Huczek Z, Filipiak KJ, Kochman J et al. Baseline platelet size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual platelet reactivity. A case-control study. Thromb Res, 2010; 125: 406-412.
27. Aksu H, Ozer O, Unal H et al. Significance of mean platelet volume on prognosis of patients with and without aspirin resistance in settings of non-ST-segment elevated acute coronary syndromes. Blood Coagul Fibrinolysis, 2009; 20: 686-693.
28. Baber U, Bander J, Karajgikar R et al. Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thromb Haemost, 2013; 110: 118-123.